{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} New Study Tracks Accelerating Use of Biomarkers in Cancer Clinical Trials

Activity Steps

Purpose of Activity

To provide information on the incorporation of biomarkers in cancer clinical trials to develop biomarker-based therapies.

Learning Objectives/Outcomes

After completing this continuing education activity you will be able to:

  1. Assess the implications of the current shift in drug development toward biomarker-based therapies.
  2. Analyze the challenges of personalized cancer therapies that are based on biomarkers.
Price: $12.95


  • ANCC 1.0 CH
  • DC - BON 1.0 CH
  • FL - BON 1.0 CH
  • GA - BON 1.0 CH

Lippincott Professional Development is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, and Georgia Board of Nursing, #50-1223.

Test Code: OT1219
Published: December 2019
Expires: 12/3/2021
Sources: Oncology Times
Required Passing Score: 7/10 (70%)
Authors: Peggy Eastman
Categories: Cancer , Oncology , Research
Specialties: Oncology
Topics: Biomarker , Cancer